DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In recent years, an association between dipeptidyl peptidase-4 (DPP-4) inhibitors and bullous pemphigoid has been detected in pharmacovigilance studies in European and Asian countries; however, no pharmacovigilance data have been published yet in the USA.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am J Clin Dermatol

Title: American journal of clinical dermatology

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1179-1888

ISSN (Print): 1175-0561

Publication date (Electronic): Nov 2021

Volume: 22

Issue: 6

Affiliations

[1 ] Division of Dermatology, University of Arizona College of Medicine - Tucson, 7165 N Pima Canyon Dr, Tucson, AZ, 85718, USA. pjedlowski@email.arizona.edu.

[2 ] Division of Dermatology, University of Arizona College of Medicine - Tucson, 7165 N Pima Canyon Dr, Tucson, AZ, 85718, USA.

[3 ] Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy, Tucson, AZ, USA.

[4 ] Division of Endocrinology, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.

[5 ] Banner University Medicine Diabetes and Endocrinology Clinic, Tucson, AZ, USA.

Article

Publisher Item ID: 10.1007/s40257-021-00625-4

DOI: 10.1007/s40257-021-00625-4

PubMed ID: 34287770

SO-VID: b5b8b5f3-8430-4c75-ae1d-23bf967f8bcb

History

Data availability:

Comments

Comment on this article

scite_

Cited by 10

See all cited by